U T MD Anderson Cancer Center Investigational Pharmacy Services
Welcome,         Profile    Billing    Logout  
 11 Trials 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Somaiah, Neeta
NCT04595747: Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Active, not recruiting
2
48
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rogaratinib, BAY-1163877, BAY1163877
National Cancer Institute (NCI)
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma, Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8, Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
01/25
01/25
DOSa, NCT04668300: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Recruiting
2
75
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Oleclumab, Anti-CD73 Monoclonal Antibody MEDI9447, MEDI9447
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Osteosarcoma, Refractory Dedifferentiated Liposarcoma, Refractory Osteosarcoma
06/26
06/26
NCT02815995: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Completed
2
56
US
Durvalumab, Tremelimumab
M.D. Anderson Cancer Center, MedImmune LLC
Advanced and/or Metastatic Sarcoma
06/24
06/24
NCT05017103: Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Terminated
2
6
US
Sintilimab, Anti-PD-1 Monoclonal Antibody IBI308, Anti-PDCD1 Monoclonal Antibody IBI308, IBI 308, IBI308
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
02/24
02/24
NCT05694871: Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Active, not recruiting
2
77
US
Palbociclib, PD-0332991, Cemiplimab, Cemiplimab RWLC, Immunoglobulin G4, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, CT Scan, Biospecimen collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
05/27
05/27
NCT06087263: Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Recruiting
2
30
US
Regorafenib, Stivarga®
M.D. Anderson Cancer Center, Bayer
Gastrointestinal Stromal Tumors
07/32
07/34
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
NCI-2018-00926, NCT03450122: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Checkmark Initiation of pivotal monotherapy trial
Mar 2018 - Mar 2018: Initiation of pivotal monotherapy trial
Completed
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dendritic Cell-targeting Lentiviral Vector ID-LV305, DCvex-NY-ESO-1, ID-LV305
M.D. Anderson Cancer Center
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
12/22
12/22
NCT06474676: T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Not yet recruiting
1
40
US
Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy, AttIL2-TIL
M.D. Anderson Cancer Center
Metastatic Soft-tissue Sarcoma
12/30
12/32
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies

Recruiting
1
258
Europe, US, RoW
NB003 tablets
Ningbo Newbay Technology Development Co., Ltd
Advanced Solid Tumor
07/25
12/25
StrateGIST 1, NCT05489237: A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: ]

Recruiting
1
240
Europe, US
IDRX-42
IDRx, Inc.
Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
04/26
09/26
Heinrich, Michael J
NCT04877522 / 2021-000602-17: Asciminib Roll-over Study

Recruiting
3
347
Europe, Canada, Japan, US, RoW
Asciminib single agent, ABL001, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel
Novartis Pharmaceuticals, Novartis Pharma AG
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
08/30
08/30
A021804, NCT04394858: Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Recruiting
2
76
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography with Contrast, Contrast Enhanced Computed Tomography, CONTRAST ENHANCED CT SCAN, Contrast-enhanced Computed Tomography, CT Scan With Contrast, CT with Contrast, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Quality-of-Life Assessment, Quality of Life Assessment, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
02/25
02/25
NCT03556384: Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

Active, not recruiting
2
23
US
Temozolomide, TEMODAR®
Adam Burgoyne, MD, PhD
Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer
06/25
06/26
NCT03610971: Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Recruiting
2
41
US
Ruxolitinib, Jakafi®, BCR-ABL Tyrosine Kinase Inhibitor (TKI), TKI
H. Lee Moffitt Cancer Center and Research Institute, H. Jean Khoury Cure CML Consortium, Incyte Corporation
Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
12/25
12/26
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT03715933: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
240
US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx, Inc.
Solid Tumors, Malignant Pleural Mesothelioma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Sarcoma, Pancreatic Adenocarcinoma, Ewing Sarcoma, Chondrosarcoma, GIST, SDH-deficient Solid Tumors
12/25
07/26
NCT04530981: A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

Completed
1
13
US
Ripretinib, QINLOCK, Repaglinide
Deciphera Pharmaceuticals, LLC
GIST - Gastrointestinal Stromal Tumor
11/23
07/24
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies

Recruiting
1
258
Europe, US, RoW
NB003 tablets
Ningbo Newbay Technology Development Co., Ltd
Advanced Solid Tumor
07/25
12/25
StrateGIST 1, NCT05489237: A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: ]

Recruiting
1
240
Europe, US
IDRX-42
IDRx, Inc.
Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
04/26
09/26
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Recruiting
1
180
Europe, Canada, US, RoW
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia
12/26
12/26

Download Options